Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Benchmark reissued a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $3.02 on Monday. The firm has a market capitalization of $84.32 million, a P/E ratio of -1.84 and a beta of -0.02. Reviva Pharmaceuticals has a 1-year low of $2.67 and a 1-year high of $9.25. The company’s fifty day moving average price is $3.66 and its 200-day moving average price is $4.14.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RVPH. Jane Street Group LLC purchased a new position in shares of Reviva Pharmaceuticals in the third quarter worth about $27,000. Wells Fargo & Company MN increased its position in Reviva Pharmaceuticals by 4,550.0% during the second quarter. Wells Fargo & Company MN now owns 5,115 shares of the company’s stock worth $30,000 after purchasing an additional 5,005 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Reviva Pharmaceuticals during the first quarter worth about $31,000. Raymond James & Associates acquired a new stake in Reviva Pharmaceuticals during the first quarter worth about $34,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Reviva Pharmaceuticals during the fourth quarter worth about $52,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.